Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat solid tumors. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors. The company is also developing PYX-107, a CD40 agonist with demonstrated anti-cancer activity in patients with several cancer indications, which is in Phase 2 clinical trial for the treatment of tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction, cancers, and pancreatic ductal adenocarcinoma. It has in-license agreement with Pfizer Inc. to develop and commercialize ADC product candidates, including micvotabart pelidotin and PYX-203, and other ADC product candidates directed to the licensed targets; and Biosion USA, Inc. for development, manufacture, and commercialization of PYX-106, an IO product candidate. Pyxis Oncology, Inc. was incorporated in 2018 and is headquartered in Boston, Massachusetts.

Pyxis Oncology Inc.

Pyxis Oncology, Inc. ( ($PYXS) ) has released its Q3 earnings. Here is a breakdown of the information Pyxis Oncology, Inc. presented to its investo...

Pyxis Oncology Reports Increased Losses Amid Development Focus

Jefferies analyst maintained a Buy rating on Pyxis Oncology today and set a price target of $7.40. In addition to Jefferies, Pyxis Oncology also re...

Jefferies Keeps Their Buy Rating on Pyxis Oncology (PYXS)

In a report released on November 3, Leonid Timashev from RBC Capital maintained a Buy rating on Pyxis Oncology, with a price target of $8.00. The c...

Market Cap	$246.57M	P/E Ratio	N/A
52W High	$5.11	52W Low	$0.83
Div Yield	N/A	Payout Ratio	N/A
EPS Growth 3Y	0.0%	52W Position	92.8%
Overall Score	71	Value Score	60
Quality Score	--	Technical Score	83

EPS Current Est	$-1.34	EPS Next Est	$-1.27
EPS Growth Est	N/A	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	PYXS	$4.80	+5.96%	726.90K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	PYXS	$4.80	+6.0%	726.90K
3
4
5
6

PYXS

PYXS

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Pyxis Oncology Inc. Data in Excel

Get Pyxis Oncology Inc. Data in Excel